Optimizing  ||| S:0 E:11 ||| JJ
management  ||| S:11 E:22 ||| NN
of  ||| S:22 E:25 ||| IN
invasive  ||| S:25 E:34 ||| JJ
mould  ||| S:34 E:40 ||| JJ
diseases  ||| S:40 E:49 ||| NNS
We  ||| S:49 E:52 ||| PRP
describe  ||| S:52 E:61 ||| VBP
an  ||| S:61 E:64 ||| DT
integrated  ||| S:64 E:75 ||| JJ
care  ||| S:75 E:80 ||| NN
pathway  ||| S:80 E:88 ||| NNS
( ||| S:88 E:89 ||| -LRB-
ICP ||| S:89 E:92 ||| NNP
)  ||| S:92 E:94 ||| -RRB-
for  ||| S:94 E:98 ||| IN
the  ||| S:98 E:102 ||| DT
optimal  ||| S:102 E:110 ||| JJ
management  ||| S:110 E:121 ||| NN
of  ||| S:121 E:124 ||| IN
invasive  ||| S:124 E:133 ||| JJ
mould  ||| S:133 E:139 ||| JJ
disease  ||| S:139 E:147 ||| NN
( ||| S:147 E:148 ||| -LRB-
IMD ||| S:148 E:151 ||| NNP
) ||| S:151 E:152 ||| -RRB-
.  ||| S:152 E:154 ||| .
The  ||| S:154 E:158 ||| DT
ICP  ||| S:158 E:162 ||| NNP
is  ||| S:162 E:165 ||| VBZ
for  ||| S:165 E:169 ||| IN
use  ||| S:169 E:173 ||| NN
by  ||| S:173 E:176 ||| IN
health  ||| S:176 E:183 ||| NN
professionals  ||| S:183 E:197 ||| NNS
involved  ||| S:197 E:206 ||| VBN
in  ||| S:206 E:209 ||| IN
the  ||| S:209 E:213 ||| DT
care  ||| S:213 E:218 ||| NN
of  ||| S:218 E:221 ||| IN
patients  ||| S:221 E:230 ||| NNS
with  ||| S:230 E:235 ||| IN
haematological  ||| S:235 E:250 ||| JJ
malignancies  ||| S:250 E:263 ||| NN
and  ||| S:263 E:267 ||| CC
haematopoietic  ||| S:267 E:282 ||| JJ
stem  ||| S:282 E:287 ||| NN
cell  ||| S:287 E:292 ||| NN
transplant  ||| S:292 E:303 ||| NN
recipients  ||| S:303 E:314 ||| NNS
who  ||| S:314 E:318 ||| WP
are  ||| S:318 E:322 ||| VBP
at  ||| S:322 E:325 ||| IN
increased  ||| S:325 E:335 ||| JJ
risk  ||| S:335 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
IMD ||| S:343 E:346 ||| NNP
.  ||| S:346 E:348 ||| .
The  ||| S:348 E:352 ||| DT
ICP  ||| S:352 E:356 ||| NNP
is  ||| S:356 E:359 ||| VBZ
not  ||| S:359 E:363 ||| RB
intended  ||| S:363 E:372 ||| VBN
for  ||| S:372 E:376 ||| IN
use  ||| S:376 E:380 ||| NN
in  ||| S:380 E:383 ||| IN
other  ||| S:383 E:389 ||| JJ
patient  ||| S:389 E:397 ||| NN
groups  ||| S:397 E:404 ||| NNS
where  ||| S:404 E:410 ||| WRB
the  ||| S:410 E:414 ||| DT
evidence  ||| S:414 E:423 ||| NN
base  ||| S:423 E:428 ||| NN
is  ||| S:428 E:431 ||| VBZ
more  ||| S:431 E:436 ||| RBR
limited ||| S:436 E:443 ||| JJ
.  ||| S:443 E:445 ||| .
The  ||| S:445 E:449 ||| DT
ICP  ||| S:449 E:453 ||| NNP
involves  ||| S:453 E:462 ||| VBZ
the  ||| S:462 E:466 ||| DT
patient  ||| S:466 E:474 ||| NN
and  ||| S:474 E:478 ||| CC
their  ||| S:478 E:484 ||| PRP$
carers ||| S:484 E:490 ||| NN
,  ||| S:490 E:492 ||| ,
as  ||| S:492 E:495 ||| RB
well  ||| S:495 E:500 ||| RB
as  ||| S:500 E:503 ||| IN
describing  ||| S:503 E:514 ||| VBG
the  ||| S:514 E:518 ||| DT
roles  ||| S:518 E:524 ||| NNS
and  ||| S:524 E:528 ||| CC
the  ||| S:528 E:532 ||| DT
complex  ||| S:532 E:540 ||| JJ
interaction  ||| S:540 E:552 ||| NN
of  ||| S:552 E:555 ||| IN
healthcare  ||| S:555 E:566 ||| JJ
professionals  ||| S:566 E:580 ||| NNS
in  ||| S:580 E:583 ||| IN
different  ||| S:583 E:593 ||| JJ
departments ||| S:593 E:604 ||| NNS
.  ||| S:604 E:606 ||| .
Therefore ||| S:606 E:615 ||| RB
,  ||| S:615 E:617 ||| ,
the  ||| S:617 E:621 ||| DT
management  ||| S:621 E:632 ||| NN
of  ||| S:632 E:635 ||| IN
IMD  ||| S:635 E:639 ||| NNP
as  ||| S:639 E:642 ||| RB
described  ||| S:642 E:652 ||| VBN
in  ||| S:652 E:655 ||| IN
the  ||| S:655 E:659 ||| DT
ICP  ||| S:659 E:663 ||| NNP
must  ||| S:663 E:668 ||| MD
be  ||| S:668 E:671 ||| VB
appropriate  ||| S:671 E:683 ||| JJ
for  ||| S:683 E:687 ||| IN
the  ||| S:687 E:691 ||| DT
overall  ||| S:691 E:699 ||| JJ
organization ||| S:699 E:711 ||| NN
,  ||| S:711 E:713 ||| ,
and  ||| S:713 E:717 ||| CC
will  ||| S:717 E:722 ||| MD
be  ||| S:722 E:725 ||| VB
dependent  ||| S:725 E:735 ||| JJ
on  ||| S:735 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
facilities  ||| S:742 E:753 ||| NNS
[ ||| S:753 E:754 ||| -LRB-
e.g.  ||| S:754 E:759 ||| FW
high-efficiency  ||| S:759 E:775 ||| FW
particulate  ||| S:775 E:787 ||| FW
air  ||| S:787 E:791 ||| FW
( ||| S:791 E:792 ||| -LRB-
HEPA ||| S:792 E:796 ||| NNP
)  ||| S:796 E:798 ||| -RRB-
filtration ||| S:798 E:808 ||| NN
]  ||| S:808 E:810 ||| -RRB-
and  ||| S:810 E:814 ||| CC
services  ||| S:814 E:823 ||| NNS
available ||| S:823 E:832 ||| JJ
.  ||| S:832 E:834 ||| .
The  ||| S:834 E:838 ||| DT
ICP  ||| S:838 E:842 ||| NNP
deals  ||| S:842 E:848 ||| NNS
with  ||| S:848 E:853 ||| IN
risk  ||| S:853 E:858 ||| NN
stratification ||| S:858 E:872 ||| NN
,  ||| S:872 E:874 ||| ,
diagnostic  ||| S:874 E:885 ||| JJ
tests ||| S:885 E:890 ||| NNS
,  ||| S:890 E:892 ||| ,
prophylactic  ||| S:892 E:905 ||| NN
and  ||| S:905 E:909 ||| CC
treatment  ||| S:909 E:919 ||| NN
strategies  ||| S:919 E:930 ||| NNS
and  ||| S:930 E:934 ||| CC
how  ||| S:934 E:938 ||| WRB
to  ||| S:938 E:941 ||| TO
incorporate  ||| S:941 E:953 ||| VB
these  ||| S:953 E:959 ||| DT
into  ||| S:959 E:964 ||| IN
the  ||| S:964 E:968 ||| DT
ICP ||| S:968 E:971 ||| NNP
.  ||| S:971 E:973 ||| .
Outpatient  ||| S:973 E:984 ||| JJ
drug  ||| S:984 E:989 ||| NN
management  ||| S:989 E:1000 ||| NN
after  ||| S:1000 E:1006 ||| IN
hospital  ||| S:1006 E:1015 ||| NN
discharge  ||| S:1015 E:1025 ||| NN
and  ||| S:1025 E:1029 ||| CC
cessation  ||| S:1029 E:1039 ||| NN
of  ||| S:1039 E:1042 ||| IN
therapy  ||| S:1042 E:1050 ||| NNS
are  ||| S:1050 E:1054 ||| VBP
outlined ||| S:1054 E:1062 ||| VBN
.  ||| S:1062 E:1064 ||| .
Local  ||| S:1064 E:1070 ||| JJ
implementation  ||| S:1070 E:1085 ||| NN
of  ||| S:1085 E:1088 ||| IN
this  ||| S:1088 E:1093 ||| DT
ICP  ||| S:1093 E:1097 ||| NNP
will  ||| S:1097 E:1102 ||| MD
vary  ||| S:1102 E:1107 ||| VB
from  ||| S:1107 E:1112 ||| IN
centre  ||| S:1112 E:1119 ||| VBG
to  ||| S:1119 E:1122 ||| TO
centre ||| S:1122 E:1128 ||| VB
:  ||| S:1128 E:1130 ||| :
the  ||| S:1130 E:1134 ||| DT
ICP  ||| S:1134 E:1138 ||| NNP
is  ||| S:1138 E:1141 ||| VBZ
a  ||| S:1141 E:1143 ||| DT
generic  ||| S:1143 E:1151 ||| JJ
template  ||| S:1151 E:1160 ||| NN
for  ||| S:1160 E:1164 ||| IN
guidance  ||| S:1164 E:1173 ||| NN
indicating  ||| S:1173 E:1184 ||| VBG
the  ||| S:1184 E:1188 ||| DT
requirements  ||| S:1188 E:1201 ||| NNS
for  ||| S:1201 E:1205 ||| IN
optimal  ||| S:1205 E:1213 ||| JJ
IMD  ||| S:1213 E:1217 ||| NNP
management  ||| S:1217 E:1228 ||| NN
and  ||| S:1228 E:1232 ||| CC
as  ||| S:1232 E:1235 ||| IN
such  ||| S:1235 E:1240 ||| JJ
provides  ||| S:1240 E:1249 ||| VBZ
a  ||| S:1249 E:1251 ||| DT
standard  ||| S:1251 E:1260 ||| NN
against  ||| S:1260 E:1268 ||| IN
which  ||| S:1268 E:1274 ||| WDT
local  ||| S:1274 E:1280 ||| JJ
practice  ||| S:1280 E:1289 ||| NN
can  ||| S:1289 E:1293 ||| MD
be  ||| S:1293 E:1296 ||| VB
audited ||| S:1296 E:1303 ||| VBN
.  ||| S:1303 E:1305 ||| .
For  ||| S:1305 E:1309 ||| IN
clinical  ||| S:1309 E:1318 ||| JJ
governance ||| S:1318 E:1328 ||| NN
,  ||| S:1328 E:1330 ||| ,
to  ||| S:1330 E:1333 ||| TO
minimize  ||| S:1333 E:1342 ||| VB
variation  ||| S:1342 E:1352 ||| NN
in  ||| S:1352 E:1355 ||| IN
practice  ||| S:1355 E:1364 ||| NN
and ||| S:1364 E:1367 ||| CC
,  ||| S:1367 E:1369 ||| ,
ultimately ||| S:1369 E:1379 ||| RB
,  ||| S:1379 E:1381 ||| ,
to  ||| S:1381 E:1384 ||| TO
improve  ||| S:1384 E:1392 ||| VB
patient  ||| S:1392 E:1400 ||| JJ
outcomes ||| S:1400 E:1408 ||| NNS
,  ||| S:1408 E:1410 ||| ,
each  ||| S:1410 E:1415 ||| DT
centre  ||| S:1415 E:1422 ||| NN
should  ||| S:1422 E:1429 ||| MD
regularly  ||| S:1429 E:1439 ||| RB
monitor  ||| S:1439 E:1447 ||| VB
and  ||| S:1447 E:1451 ||| CC
document  ||| S:1451 E:1460 ||| NN
compliance  ||| S:1460 E:1471 ||| NN
with  ||| S:1471 E:1476 ||| IN
the  ||| S:1476 E:1480 ||| DT
local  ||| S:1480 E:1486 ||| JJ
ICP ||| S:1486 E:1489 ||| NNP
,  ||| S:1489 E:1491 ||| ,
from  ||| S:1491 E:1496 ||| IN
provision  ||| S:1496 E:1506 ||| NN
of  ||| S:1506 E:1509 ||| IN
patient  ||| S:1509 E:1517 ||| JJ
information ||| S:1517 E:1528 ||| NN
,  ||| S:1528 E:1530 ||| ,
appropriate  ||| S:1530 E:1542 ||| JJ
prescribing  ||| S:1542 E:1554 ||| NN
and  ||| S:1554 E:1558 ||| CC
diagnostic  ||| S:1558 E:1569 ||| JJ
investigation  ||| S:1569 E:1583 ||| NN
to  ||| S:1583 E:1586 ||| TO
clinical  ||| S:1586 E:1595 ||| JJ
outcomes ||| S:1595 E:1603 ||| NNS
.  ||| S:1603 E:1605 ||| .
